Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 7/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | ACSL1 | P33121 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28853967 | 0.83 | MAPKAPK2 (0.56) | MAPKAPK2MAOAMAOBNPC1LMNA | |
| SCHEMBL31470407 | 0.78 | MAOA (0.59) | MAPKAPK2MAOAMAOBNPC1LMNA | |
| SCHEMBL88260 | 0.78 | MAOA (0.59) | MAPKAPK2MAOAMAOBNPC1LMNA | |
| Hydrochloric Acid SCHEMBL28586545 | 0.76 | MAOA (0.57) | MAPKAPK2MAOAMAOBNPC1LMNA | |
| SCHEMBL17845256 | 0.74 | MAOA (0.65) | MAPKAPK2MAOAMAOBNPC1LMNA | |
| Xanthene SCHEMBL27837879 | 0.72 | MAOA (0.85) | MAPKAPK2MAOAMAOBNPC1LMNA | |
| SCHEMBL1461767 | 0.71 | MAPKAPK2 (0.57) | MAPKAPK2MAOAMAOBNPC1LMNA | |
| SCHEMBL3690493 | 0.70 | MAOA (0.59) | MAPKAPK2MAOAMAOBNPC1LMNA | |
| Xanthene SCHEMBL4267 | 0.70 | MAOA (1.00) | MAPKAPK2MAOAMAOBNPC1LMNA | |
| Xanthene SCHEMBL29378346 | 0.70 | MAOA (1.00) | MAPKAPK2MAOAMAOBNPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7038037-B2 | Method for sequential support-bound synthesis of conjugated oligomeric compounds | ISIS PHARMACEUTICALS, INC. (US) | 2006-05-02 | — | — | US | disclosed |
| US-20040006203-A1 | Method for sequential support-bound synthesis of conjugated oligomeric compounds | ISIS PHARMACEUTICALS, INC. | 2004-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006203-A1 | Method for sequential support-bound synthesis of conjugated oligomeric compounds | PCNA, MSN, SSBP1 | MAPKAPK2 3531/4885MAOA 1808/4885MAOB 1494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.